PresseBox
Press release BoxID: 710926 (MediGene AG)
  • MediGene AG
  • Lochhamer Str. 11
  • 82152 Planegg/Martinsried
  • https://www.medigene.de
  • Contact person
  • Julia Hofmann
  • +49 (89) 85653324

Medigene to Participate in Five Investment and Scientific Conferences in November

(PresseBox) (Planegg/Martinsried , ) Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in five international conferences:

BIO-Europe - Annual International Partnering Conference
Date: 3 - 5 November 2014
Location: Frankfurt am Main, Germany

The Society for Immunotherapy of Cancer (SITC)
Date: 7 - 9 November 2014
Location: National Harbor (Washington D.C.), USA
Poster Presentation on 8 November focusing the TCR immunotherapy platform titled "Generation of tumor antigen-specific CD4+ and CD8+ T cells by simultaneous MHC-I and -II epitope presentation in vitro and in vivo"

Jefferies Global Healthcare Conference
Date: 19 - 20 November 2014
Location: London, Great Britain

German Equity Forum
Date: 24 - 26 November 2014
Location: Frankfurt am Main, Germany
Company Presentation at 25 November 5 pm

BayImmuNet - International Symposium on Interventional Immunology from Cells to Drugs
Date: 13 - 14 November 2014
Location: Regensburg, Germany
Chair: Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

MediGene AG

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.